# A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

> **NCT03637491** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 36 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Binimetinib
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT03637491
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-15
- **Primary completion:** 2020-12-03
- **Final completion:** 2021-02-02
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Available clinical data has shown limited anti-tumor activity and reaching target study drug dose levels may not be feasible.
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03637491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03637491, "A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03637491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*